Global Idiopathic Intracranial Hypertension Treatment Market Size to Grow at a CAGR of 4.27% During the Forecast Period of 2023-2031

Published January 30, 2023


The ‘Global Idiopathic Intracranial Hypertension Treatment Market Size, Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global idiopathic intracranial hypertension treatment market, assessing the market on the basis of its segments like diagnostic method, treatment channel, and major regions.

Idiopathic Intracranial Hypertension Treatment Market Size, Share, Price Trends, Industry Report, Key Players, Major Segments, and Forecast

The key highlights of the report include:

Market Overview (2016-2031)

• Forecast CAGR (2023-2031): 4.27%

The growth of the idiopathic intracranial hypertension treatment market is driven by a number of factors, including an increasing incidence of the condition, improved diagnostic techniques, and the development of new treatments. The incidence of Idiopathic Intracranial Hypertension (IIH) is increasing, particularly in obese women of childbearing age. This is due to the growing obesity epidemic and the fact that IIH is more common in women. As a result, the demand for effective treatments is increasing.

Moreover, the rapid advances in diagnostic techniques have led to a better understanding of the condition and have allowed for earlier diagnosis. This has led to an increase in the number of people seeking treatment, which has driven the market growth.

Get a Free Sample Report with Table of Contents:

The development of new treatments has also contributed to the growth of the market. For example, the use of drugs such as acetazolamide and topiramate has been shown to be effective in treating IIH. Additionally, new surgical treatments, such as optic nerve sheath fenestration, have also been developed to treat the condition.
The growing awareness of the condition has also helped to drive the market growth. This is because more people are aware of the condition and are seeking treatment. Government initiatives and funding to support research and development have also played a pivotal role in the growth of the market.

Idiopathic Intracranial Hypertension Treatment Industry Definition and Major Segments

Idiopathic intracranial hypertension (IIH) treatment is the management of increased pressure within the skull that is not caused by a known or identifiable underlying condition. Treatment options include weight loss and lifestyle changes, medications to reduce fluid build-up in the brain, and in severe cases, surgical interventions to relieve pressure. The goal of treatment is to improve symptoms and prevent vision loss or other complications. It is important to work closely with a healthcare provider to determine the best course of treatment for an individual with IIH.

Market Breakup by Diagnosis Method

  •  Carbonic Anhydrase Inhibitors
    •  Acetazolamide
    •  Methazolamide
    •  Others
  •  Loop Diuretics
    •  Furosemide
    •  Others
  •  Corticosteroids
  • Anticonvulsant
    •  Topiramate

• Others

Market Breakup by Treatment Channel

• Public
• Private

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Read Full Report with Table of Contents:

Idiopathic Intracranial Hypertension Treatment Market Trends

The growth of the market is primarily driven by the technological advancements in the market. Researchers have been developing new medications that specifically target the underlying causes of idiopathic intracranial hypertension (IIH), such as reducing cerebrospinal fluid production or decreasing blood vessel constriction. These new drugs may offer more effective and targeted treatment options for patients. Medical technology advancements have led to the development of minimally invasive procedures for the treatment of IIH, such as lumbar puncture with intrathecal pressure measurement and optic nerve sheath fenestration. These procedures offer an alternative to traditional surgical treatments, which can be invasive and carry a higher risk of complications.

Combination therapies, such as using medications in combination with weight loss, have been found to be more effective in treating IIH than using medications alone. This approach can help improve symptoms and prevent the progression of the condition. Telemedicine is also becoming more widely adopted, patients with IIH may have increased access to specialists and remote monitoring, which can improve treatment outcomes. This can also help reduce the burden on patients who have to travel long distances to see a specialist.

Moreover, Patient education and support programs have been found to be beneficial in managing the symptoms of IIH. These programs can provide patients with information on the condition, help them understand their treatment options, and provide support to help them manage the condition.

Key Market Players

The major players in the idiopathic intracranial hypertension treatment market report are Teva Pharmaceutical Industries Ltd, Mylan N.V., Pfizer, Inc., Upsher-Smith Laboratories, LLC, Merck & Co., Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Astellas Pharma Inc., AbbVie Inc., Cadila Healthcare Ltd., Sun Pharmaceutical Industries Ltd., and Sanofi. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

The report studies the latest updates in the market, along with their impact across the market. It also analyses the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.

More Reports

North America Drywall Market: 

North America Alternative Proteins Market:

Middle East and Africa Intravenous Solutions Market:

Europe Rainwater Harvesting Market:

United States Alternative Proteins Market:

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact

Company Name: Claight Corporation
Contact Person: Sophia Grace, Business Consultant
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA